CLAUDINS 1, 3, 4, 7 AND 10-YEAR SURVIVAL IN TRIPLE-NEGATIVE BREAST TUMORS

Authors

  • Marcia Silveira Graudenz Universidade Federal do Rio Grande do Sul https://orcid.org/0000-0002-5872-9537
  • Ermani Cadore Universidade Federal do Rio Grande do Sul https://orcid.org/0000-0002-2253-4594
  • Bruna Pellini Ferreira Universidade Federal do Rio Grande do Sul
  • Renata Schulz Universidade Federal do Rio Grande do Sul
  • Clarissa Borba Universidade Federal do Rio Grande do Sul
  • Diego Uchoa Universidade Federal do Rio Grande do Sul
  • Mario Bernardes Wagner Universidade Federal do Rio Grande do Sul

Keywords:

Breast cancer, claudins, survival analysis, pathology, gynecology

Abstract

Purpose: Breast cancer is a major cause of morbidity and mortality and is known to be a heterogeneous disease. The clinical and molecular characterization of its subtypes is critical to guide its prognosis and treatment. The study of the expression of Claudins (CLDN) might help in the characterization of these tumors. This study investigated the association of expression of CLDN-1, CLDN-3, CLDN-4 and CLDN-7 with 10-year survival in a series of triple-negative breast cancers. Methods: Eighty triple negative tumors were analyzed by automated immunohistochemistry for CLDN-1, CLDN-3, CLDN-4 and CLDN-7. The immunohistochemical expression was assessed by the H-Score (intensity multiplied by the percentage of staining on membrane). The associations between the expression of CLDN and 10-year survival were evaluated by Kaplan-Meier curves and Cox regressions. Results: Positive expression (H-score ≥50) of CLDN-1, CLDN-3, CLDN-4 and CLDN-7 were observed in 41.3, 77.5, 67.5 and 18.8% of the cohort, respectively. Patients with positive CLDN-1 expression had a significant lower survival than their counterparts [HR=2.37 (95%CI 1.19–4.72)]. Further, CLDN-3 was inversely associated with overall survival. Patients with positive expression of CLDN-1 and negative expression of CLDN-3 had a HR 10.4 (95%CI 3.40–31.8) higher than patients with negative expression of CLDN-1 and positive expression of CLDN-3. Neither CLDN-4 nor CLDN-7 expression was associated with 10-year survival. Conclusions: Differential expression of CLDN can help in clinicopathological characterization of triple-negative tumors. Moreover, CLDN-1 and CLDN-3 appear to be important prognostic factors for these tumors.

Downloads

Download data is not yet available.

Author Biography

Marcia Silveira Graudenz, Universidade Federal do Rio Grande do Sul

Faculdade de Medicina, Universidade Federal do Rio Grande do Sul

References

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917. https://doi. org/10.1002/ijc.25516

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. https://doi.org/10.1038/35021093

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-74. https://doi.org/10.1073/ pnas.191367098

Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007;7(10):791-9. https://doi.org/10.1038/nrc2212

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429- 34. https://doi.org/10.1158/1078-0432.CCR-06-3045

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492- 502. https://doi.org/10.1001/jama.295.21.2492

Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100(18):10393-8. https://doi.org/10.1073/ pnas.1732912100

Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5-23. https://doi. org/10.1016/j.molonc.2010.11.003 9. Reddy KB. Triple-negative breast cancers: an updated review on treatment options. Curr Oncol. 2011;18(4):e173-9. REFERENCES

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24(36):5652-7. https://doi. org/10.1200/JCO.2006.06.5664

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-34. https://doi.org/10.1158/1078-0432.CCR-06-1109

Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol. 1998;141(7):1539-50.

Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J, Blasig IE. Structure and function of claudins. Biochimica Biophysica Acta. 2008;1778(3):631-45. https://doi.org/10.1016/j. bbamem.2007.10.018

Mineta K, Yamamoto Y, Yamazaki Y, Tanaka H, Tada Y, Saito K, et al. Predicted expansion of the claudin multigene family. FEBS Lett. 2011;585(4):606-12. https://doi.org/10.1016/j. febslet.2011.01.028

Ma F, Ding X, Fan Y, Ying J, Zheng S, Lu N, et al. A CLDN1- Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer. PLOS ONE. 2014;9(11):e112765. https://doi. org/10.1371/journal.pone.0112765

Kolokytha P, Yiannou P, Keramopoulos D, Kolokythas A, Nonni A, Patsouris E, et al. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer. Appl Immunohistochem Mol Morphol. 2014;22(2):125– 31. https://doi.org/10.1097/pai.0b013e31828d9d62

Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke C, Soares FA, et al. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer. Oncology Reports. 2012;27(1):28-38. https://doi.org/10.3892/or.2011.1477

Blanchard AA, Skliris GP, Watson PH, Murphy LC, Penner C, Tomes L, et al. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch. 2009;454(6):647-56. https://doi. org/10.1007/s00428-009-0770-6

Detre S, Saclani Jotti G, Dowsett M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48(9):876-8.

Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009;15(7):2302-10. https://doi.org/10.1158/1078- 0432.CCR-08-2132

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368-76. https://doi.org/10.1158/1078- 0432.CCR-07-1658

Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2011;16(Suppl. 1):61-70. https://doi. org/10.1634/theoncologist.2011-S1-61

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418-23. https://doi.org/10.1073/pnas.0932692100

Chen LH, Kuo WH, Tsai MH, Chen PC, Hsiao CK, Chuang EY, et al. Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan. PLoS One. 2011;6(11):e28222. https://dx.doi. org/10.1371%2Fjournal.pone.0028222

Gucalp A, Traina TA. Triple-Negative Breast Cancer: Adjuvant Therapeutic Options. Chemother Res Pract. 2011;2011:696208. https://doi.org/10.1155/2011/696208

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684-91. https://doi. org/10.1200/JCO.2009.24.9284

Morohashi S, Kusumi T, Sato F, Odagiri H, Chiba H, Yoshihara S, et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med. 2007;20(2):139-43.

Szasz AM, Tokes AM, Micsinai M, Krenacs T, Jakab C, Lukacs L, et al. Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin Exp Metastasis. 2011;28(1):55-63. https://doi.org/10.1007/s10585-010-9357-5

McClane BA, Hanna PC, Wnek AP. Clostridium perfringens enterotoxin. Microb Pathol. 1988;4(5):317-23.

Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Argani P, et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol. 2004;164(5):1627- 33. https://doi.org/10.1016/S0002-9440(10)63721-2

Downloads

Published

2019-04-05

How to Cite

Graudenz, M. S., Cadore, E., Ferreira, B. P., Schulz, R., Borba, C., Uchoa, D., & Wagner, M. B. (2019). CLAUDINS 1, 3, 4, 7 AND 10-YEAR SURVIVAL IN TRIPLE-NEGATIVE BREAST TUMORS. Mastology, 29(2), 71–78. Retrieved from https://revistamastology.emnuvens.com.br/revista/article/view/580

Issue

Vol. 29 No. 2 (2019)

Section

Original Articles

License

Copyright (c) 2019 Marcia Silveira Graudenz, Ermani Cadore, Bruna Pellini Ferreira, Renata Schulz, Clarissa Borba, Diego Uchoa, Mario Bernardes Wagner

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.